[ScinoPharm] May 2026 Revenue of NT$175 Million (YoY -33.2%)
NQ Score
31/100
N1 Content Completeness
3
AI Summary (NQ-processed)
ScinoPharm Taiwan (TWSE: 1789), operating in the biotech and medical industry, announced its monthly revenue for May 2026 reached NT$175,224 thousand (approx. NT$175 million), representing a 33.2% decrease compared to the same month last year.
AI Analysis
Frequently Asked Questions
- Q: What was ScinoPharm's revenue for May 2026?
- A: The monthly revenue was NT$175,224 thousand (approximately NT$175 million), representing a 33.2% year-on-year decrease.
- Q: What is ScinoPharm's core business?
- A: The company specializes in the development and manufacturing of Active Pharmaceutical Ingredients (APIs) and provides CDMO services.
- Q: What is ScinoPharm's stock listing code?
- A: Its listing code on the Taiwan Stock Exchange (TWSE) is 1789.